
Cydar Medical Ltd raises €10.5m in Series A financing
Besides Pembroke Venture Capital Trust as cornerstone investor with €3.7m (£3m), new investor Downing LLP and existing seed investors supported the...

Free sugar linked to higher cardiovascular disease
The findings of a group headed by Rebecca Kelly at University Oxford (doi: 10.1186/s12916-022-02712-7) strengthen the evidence for the global...

First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...

Chong Kun Dang Pharm licences Synaffix ADC platform
Though the companies did not give any financial details, former licencing deals of Synaffix to global pharma companies such as Amgen or ranged...

Minaris and LIfT BioSciences collaborate in cell therapy development
LIfT BioSciences wants to start its first-in-human clinical trials with an allogeneic neutrophil progenitor-based cell therapy in first Quartal...

Germany’s Curevac offers common shares
In addition to these ordinary shares, Tübingen-based CureVac is enticing investors to give up another 15% of the number of ordinary shares under the...